Pharmaceutical intelligence for Millennium Pharmaceuticals, Inc. with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 1
Assets: 2

Recent signals(1)

ClinicalJuly 1, 2026

Phase III Trial of Ixazomib and Lenalidomide in Solitary Plasmacytoma Post-Radiation

A phase III trial is underway comparing ixazomib citrate, lenalidomide, dexamethasone, and zoledronic acid versus zoledronic acid alone after radiation therapy for solitary plasmacytoma of bone.

Upcoming catalysts

No catalysts indexed for this entity yet.

Regulatory activity

No signals indexed for this entity yet.

Clinical activity(1)

ClinicalJuly 1, 2026

Phase III Trial of Ixazomib and Lenalidomide in Solitary Plasmacytoma Post-Radiation

A phase III trial is underway comparing ixazomib citrate, lenalidomide, dexamethasone, and zoledronic acid versus zoledronic acid alone after radiation therapy for solitary plasmacytoma of bone.

Competitive activity

No signals indexed for this entity yet.

Assets

Phase →

Trial Update →

Therapeutic areas

Multiple Myeloma →

Oncology →

Oncology · Multiple Myeloma →

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.